Completed PHASE1 INTERVENTIONAL 5-arm NCT02022163

Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults.

Sponsor: Health Sciences Centre, Winnipeg, Manitoba

Conditions RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Interventions High dose of H7 VLP vaccine High dose of H7 VLP vaccine + Alhydrogel Low dose of H7 VLP vaccine + Alhydrogel Med dose of H7 VLP vaccine + Alhydrogel Placebo

Updated 6 times since 2017 Last updated: Sep 24, 2015 Started: Dec 31, 2013 Primary completion: Sep 30, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on RNA Virus Infections and Respiratory Tract Diseases, this trial is completed. The trial is conducted by Health Sciences Centre, Winnipeg, Manitoba and has accumulated 6 data snapshots since 2013. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2019 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Jan 2019 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Dec 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Health Sciences Centre, Winnipeg, Manitoba
Medicago
Public Health Agency of Canada (PHAC)
Syneos Health

Data source: Medicago

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Winnipeg, Canada